학술논문
Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection
Document Type
Article
Author
Sheikh-Mohamed, Salma; Isho, Baweleta; Chao, Gary Y.C.; Zuo, Michelle; Cohen, Carmit; Lustig, Yaniv; Nahass, George R.; Salomon-Shulman, Rachel E.; Blacker, Grace; Fazel-Zarandi, Mahya; Rathod, Bhavisha; Colwill, Karen; Jamal, Alainna; Li, Zhijie; de Launay, Keelia Quinn; Takaoka, Alyson; Garnham-Takaoka, Julia; Patel, Anjali; Fahim, Christine; Paterson, Aimee; Li, Angel Xinliu; Haq, Nazrana; Barati, Shiva; Gilbert, Lois; Green, Karen; Mozafarihashjin, Mohammad; Samaan, Philip; Budylowski, Patrick; Siqueira, Walter L.; Mubareka, Samira; Ostrowski, Mario; Rini, James M.; Rojas, Olga L.; Weissman, Irving L.; Tal, Michal Caspi; McGeer, Allison; Regev-Yochay, Gili; Straus, Sharon; Gingras, Anne-Claude; Gommerman, Jennifer L.
Source
Mucosal immunology; August 2022, Vol. 15 Issue: 5 p799-808, 10p
Subject
Language
ISSN
19330219; 19353456
Abstract
Although SARS-CoV-2 infects the upper respiratory tract, we know little about the amount, type, and kinetics of antibodies (Ab) generated in the oral cavity in response to COVID-19 vaccination. We collected serum and saliva samples from participants receiving two doses of mRNA COVID-19 vaccines and measured the level of anti-SARS-CoV-2 Ab. We detected anti-Spike and anti-Receptor Binding Domain (RBD) IgG and IgA, as well as anti-Spike/RBD associated secretory component in the saliva of most participants after dose 1. Administration of a second dose of mRNA boosted the IgG but not the IgA response, with only 30% of participants remaining positive for IgA at this timepoint. At 6 months post-dose 2, these participants exhibited diminished anti-Spike/RBD IgG levels, although secretory component-associated anti-Spike Ab were more stable. Examining two prospective cohorts we found that participants who experienced breakthrough infections with SARS-CoV-2 variants had lower levels of vaccine-induced serum anti-Spike/RBD IgA at 2–4 weeks post-dose 2 compared to participants who did not experience an infection, whereas IgG levels were comparable between groups. These data suggest that COVID-19 vaccines that elicit a durable IgA response may have utility in preventing infection.